Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets
Coralea Kappel(McMaster University), Srikala S. Sridhar(Princess Margaret Cancer Centre), Adrian G. Sacher(Princess Margaret Cancer Centre), Tracy Stockley(University Health Network), Tong Zhang(University Health Network), Nazanin Fallah‐Rad(Princess Margaret Cancer Centre), Shamini Selvarajah(University Health Network), Evan W. Warner(Guardant (United States)), Di Jiang(Hong Kong Polytechnic University), Aaron R. Hansen(Princess Margaret Cancer Centre), Bryan Wong(Princess Margaret Cancer Centre), Philippe L. Bédard(Princess Margaret Cancer Centre)
Cited by 3
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846